ClinicalTrials.gg
CompletedNCT04402489Updated Dec 30, 2025Results posted

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

A Phase 3 interventional study of Placebo and MT-7117 Low Dose in EPP and XLP, sponsored by Tanabe Pharma America, Inc.. Completed at 31 sites in 10 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP aged 12-75.

02

Conditions studied

  • EPP
  • XLP
03

In context

Lead sponsor

Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Additional screening criteria check may apply for qualification.

Inclusion criteria

Inclusion Criteria:

  1. Subjects provided written to participate. For minor subjects, both minor assent and parental consent will be provided.
  2. Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical history, aged 12 years to 75 years, inclusive, at Screening.
  3. Subjects have a body weight of ≥30 kg.
  4. Subjects are willing and able to travel to the study sites for all scheduled visits.
  5. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel).
  6. Female subjects who are non-lactating and have a negative urine pregnancy test at baseline visit prior to receiving the first dose of study drug.
  7. Female subjects of and male subjects with partner of child-bearing potential currently using/willing to use 2 effective methods of including barrier method as described in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of photodermatoses other than EPP or XLP.
  2. Subjects who are unwilling or unable to go outside during daylight hours most days (e.g., between 1 hour post sunrise and 1 hour pre-sunset) during the study.
  3. Presence of hepatobiliary disease based on LFT values at Screening.
  4. Subjects with , ALT, ALP ≥3.0 × (ULN) or total >1.5 × ULN at Screening.
  5. Subjects with or having a history (in the last 2 years) of excessive alcohol intake in the opinion of the Investigator.
  6. History of melanoma.
  7. Presence of melanoma and/or lesions suspicious for melanoma at Screening.
  8. History of familial melanoma (defined as having 2 or more first-degree relatives, such as parents, sibling and/or child).
  9. Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions.

    Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or nevi cannot be resolved through or excision, the subject will be excluded from the study.

  10. History or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subjects.
  11. Presence of clinically significant acute or chronic renal disease based upon the subject's medical records including hemodialysis; an estimated (eGFR) \<60 mL/min as calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKDEPI) creatinine equation (2009) for adults and by the Schwartz creatinine equation for adolescents (2009). Modification of Diet in Renal Disease (MDRD) can be used for adults per local recommendations.
  12. Presence of any clinically significant disease or laboratory abnormality which, in the opinion of the Investigator, can interfere with the study objectives and/or safety of the subjects.
  13. Female subjects who are pregnant, lactating, or intending to become pregnant during the study.
  14. Treatment with phototherapy within 3 months before Randomization (Visit 2).
  15. Treatment with afamelanotide within 3 months before Randomization (Visit 2).
  16. Treatment with cimetidine within 4 weeks before Randomization (Visit 2).
  17. Treatment with antioxidant agents within 4 weeks before Randomization (Visit 2), at doses which, in the opinion of the Investigator, may affect study endpoints (including but not limited to beta-carotene, cysteine, pyridoxine).
  18. Chronic treatment with any scheduled analgesic agents including, but not limited to, opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl, or their combination with other unscheduled analgesics or non-steroidal anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4 weeks before Randomization (Visit 2).

    Acute use of scheduled narcotics greater than 3 months prior to randomization, OTCs, such as NSAIDs or aspirin for analgesia, or prior temporary use of scheduled agents within 3 months of screening are not excluded.

  19. Treatment with any drugs or supplements which, in the opinion of the Investigator, can interfere with the objectives of the study or safety of the subjects.
  20. Previous exposure to MT-7117 (this does not include placebo treated subjects).
  21. Previous treatment with any agent within 12 weeks before Screening OR 5 half-lives of the investigational product (whichever is longer).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
184 participants (actual)

Study arms

  • Placebo comparator
    Placebo Comparator

    Oral tablet of placebo once a day.

    Drug: Placebo

  • Experimental
    MT-7117 Low Dose

    Oral tablet of MT-7117 Low Dose once a day.

    Drug: MT-7117 Low Dose

  • Experimental
    MT-7117 High Dose

    Oral tablet of MT-7117 High Dose once a day.

    Drug: MT-7117 High Dose

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-sunset at Week 26 (Visit 7)

    Time frame: From 1 hour post-sunrise to 1 hour pre-sunset at Week 26 (Visit 7)

Secondary outcomes

  1. Patient Global Impression of Change (PGIC) at Week 26

    PGIC: Scale from 1 to 7, where 7 is worse.

    Time frame: Week 26

  2. Total Number of Sunlight-induced Pain Events Defined as Prodrome Symptoms (Burning, Tingling, Itching, or Stinging) With Pain Rating of 1-10 on the Likert Scale During the 26-week Double-blind Treatment Period.

    The Likert scale used ranges from 0 to 10, where 0 indicates the lowest pain rating and 10 indicates the highest pain rating. Likewise, 0 indicates to best outcome and 10 indicates the worst outcome. The sum of the number of pain events with pain rating of 1 to 10 for the day is used as the number of sunlight-induced pain events in the day. The sum of the number of the pain events with pain rating of 1 to 10 in each day during the 26-week Double-blind Treatment Period is calculated as this endpoint.

    Time frame: During the 26-week double-blind treatment period

  3. Change From Baseline for Total Score in the Domain of Pain Intensity in the PROMIS-57 at Week 26

    Pain intensity: 0 to 10, where 10 is worst pain imaginable.

    Time frame: Baseline (Week 0) and Week 26

  4. The Percentage of Subjects Who Are Responders

    The percentage of subjects who are responders based on average daily sunlight exposure time to first prodromal symptom associated with sunlight exposure between 1 hour post-sunrise and 1 hour presunset defined by within-subject meaningful change of 66 minutes increase from baseline to Week 26

    Time frame: Week 26

  5. Change From Baseline for Total Score in the Domain of Physical Function in the PROMIS-57 at Week 26

    Physical function: 1-5, where 5 is without any difficulty.

    Time frame: Baseline (Week 0) and Week 26

07

Results

Posted Mar 21, 2025

Participant flow

26 Weeks Double-Blind Treatment (DBT)
Participant flow — 26 Weeks Double-Blind Treatment (DBT)
MilestonePlaceboMT-7117 Low DoseMT-7117 High DosePlacebo -> MT-7117 Low DosePlacebo -> MT-7117 High Dose
Started61636000
Completed57605800
Not completed43200
Withdrew: Adverse event01000
Withdrew: Physician decision10000
Withdrew: Withdrawal by subject32200
26 Weeks Double-Blind Extension (DBE)
Participant flow — 26 Weeks Double-Blind Extension (DBE)
MilestonePlaceboMT-7117 Low DoseMT-7117 High DosePlacebo -> MT-7117 Low DosePlacebo -> MT-7117 High Dose
Started056552828
Completed055522728
Not completed01310
Withdrew: Adverse event00100
Withdrew: Lost to follow-up00010
Withdrew: Withdrawal by subject01200

Outcome measures

PrimaryChange From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-sunset at Week 26 (Visit 7)
Time frame:
From 1 hour post-sunrise to 1 hour pre-sunset at Week 26 (Visit 7)
Reported as:
Least squares mean · minute
Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-sunset at Week 26 (Visit 7)
minuteDBT ITT1 PlaceboDBT ITT1 MT- 7117 Low DoseDBT ITT1 MT- 7117 High Dose
Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-sunset at Week 26 (Visit 7)20.59 ± 10.2930.39 ± 10.0443.29 ± 10.13
Statistical analysis
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 Low Dose · Mixed-effect model for repeated measures · p = 0.496 · Least square mean difference vs placebo: 9.8 · 95% CI -18.52 to 38.12
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 High Dose · Mixed-effect model for repeated measures · p = 0.116 · Least square mean difference vs placebo: 22.7 · 95% CI -5.68 to 51.09
SecondaryPatient Global Impression of Change (PGIC) at Week 26

PGIC: Scale from 1 to 7, where 7 is worse.

Time frame:
Week 26
Reported as:
Least squares mean · point
Patient Global Impression of Change (PGIC) at Week 26
pointDBT ITT1 PlaceboDBT ITT1 MT- 7117 Low DoseDBT ITT1 MT- 7117 High Dose
Patient Global Impression of Change (PGIC) at Week 263.25 ± 1.142.41 ± 0.141.82 ± 0.14
Statistical analysis
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 Low Dose · Mixed-effect model for repeated measures · p = < 0.001 · Least square mean difference vs placebo: -0.84 · 95% CI -1.23 to -0.44
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 High Dose · Mixed-effect model for repeated measures · p = < 0.001 · Least square mean difference vs placebo: -1.43 · 95% CI -1.83 to -1.03
SecondaryTotal Number of Sunlight-induced Pain Events Defined as Prodrome Symptoms (Burning, Tingling, Itching, or Stinging) With Pain Rating of 1-10 on the Likert Scale During the 26-week Double-blind Treatment Period.

The Likert scale used ranges from 0 to 10, where 0 indicates the lowest pain rating and 10 indicates the highest pain rating. Likewise, 0 indicates to best outcome and 10 indicates the worst outcome. The sum of the number of pain events with pain rating of 1 to 10 for the day is used as the number of sunlight-induced pain events in the day. The sum of the number of the pain events with pain rating of 1 to 10 in each day during the 26-week Double-blind Treatment Period is calculated as this endpoint.

Time frame:
During the 26-week double-blind treatment period
Reported as:
Geometric mean · events
Total Number of Sunlight-induced Pain Events Defined as Prodrome Symptoms (Burning, Tingling, Itching, or Stinging) With Pain Rating of 1-10 on the Likert Scale During the 26-week Double-blind Treatment Period.
eventsDBT ITT1 PlaceboDBT ITT1 MT- 7117 Low DoseDBT ITT1 MT- 7117 High Dose
Total Number of Sunlight-induced Pain Events Defined as Prodrome Symptoms (Burning, Tingling, Itching, or Stinging) With Pain Rating of 1-10 on the Likert Scale During the 26-week Double-blind Treatment Period.23.9 ± 30.9315.87 ± 22.0513.78 ± 18.7
Statistical analysis
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 Low Dose · Refer to comments below: · p = 0.199 · Incident rate ratio: 0.76 · 95% CI 0.49 to 1.16Negative binomial regression model with log link was used for other method.
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 High Dose · Refer to comments below: · p = 0.006 · Incident rate ratio: 0.55 · 95% CI 0.36 to 0.84Negative binomial regression model with log link was used for other method.
SecondaryChange From Baseline for Total Score in the Domain of Pain Intensity in the PROMIS-57 at Week 26

Pain intensity: 0 to 10, where 10 is worst pain imaginable.

Time frame:
Baseline (Week 0) and Week 26
Reported as:
Least squares mean · total score
Change From Baseline for Total Score in the Domain of Pain Intensity in the PROMIS-57 at Week 26
total scoreDBT ITT1 PlaceboDBT ITT1 MT- 7117 Low DoseDBT ITT1 MT- 7117 High Dose
Change From Baseline for Total Score in the Domain of Pain Intensity in the PROMIS-57 at Week 26-1.42 ± 0.18-1.56 ± 0.16-1.65 ± 0.17
Statistical analysis
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 Low Dose · mixed-effect model for repeated measures · p = 0.55 · Least square mean difference vs placebo: -0.15 · 95% CI -0.62 to 0.33
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 High Dose · mixed-effect model for repeated measures · p = 0.343 · Least square mean difference vs placebo: -0.23 · 95% CI -0.72 to 0.25
SecondaryThe Percentage of Subjects Who Are Responders

The percentage of subjects who are responders based on average daily sunlight exposure time to first prodromal symptom associated with sunlight exposure between 1 hour post-sunrise and 1 hour presunset defined by within-subject meaningful change of 66 minutes increase from baseline to Week 26

Time frame:
Week 26
Reported as:
Number · percentage of participants
The Percentage of Subjects Who Are Responders
percentage of participantsDBT ITT1 PlaceboDBT ITT1 MT- 7117 Low DoseDBT ITT1 MT- 7117 High Dose
The Percentage of Subjects Who Are Responders121116
Statistical analysis
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 Low Dose · Regression, Logistic · p = 0.642 · Odds ratio (or): 0.805 · 95% CI 0.323 to 2.007
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 High Dose · Regression, Logistic · p = 0.431 · Odds ratio (or): 1.412 · 95% CI 0.598 to 3.336
SecondaryChange From Baseline for Total Score in the Domain of Physical Function in the PROMIS-57 at Week 26

Physical function: 1-5, where 5 is without any difficulty.

Time frame:
Baseline (Week 0) and Week 26
Reported as:
Least squares mean · total score
Change From Baseline for Total Score in the Domain of Physical Function in the PROMIS-57 at Week 26
total scoreDBT ITT1 PlaceboDBT ITT1 MT- 7117 Low DoseDBT ITT1 MT- 7117 High Dose
Change From Baseline for Total Score in the Domain of Physical Function in the PROMIS-57 at Week 260.67 ± 0.361.54 ± 0.321.22 ± 0.33
Statistical analysis
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 Low Dose · mixed-effect model for repeated measures · p = 0.072 · Least square mean difference vs placebo: 0.87 · 95% CI -0.08 to 1.82
  • DBT ITT1 Placebo vs DBT ITT1 MT- 7117 High Dose · mixed-effect model for repeated measures · p = 0.252 · Least square mean difference vs placebo: 0.56 · 95% CI -0.4 to 1.51

Adverse events

Collected over through study completion, an average of 58 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBT: Placebo0/61 (0%)0/61 (0%)30/61 (49.2%)
DBT: MT-7117 Low Dose0/63 (0%)2/63 (3.2%)35/63 (55.6%)
DBT: MT-7117 High Dose1/60 (1.7%)2/60 (3.3%)40/60 (66.7%)
DBE: MT-7117 Low Dose Switched From Placebo0/28 (0%)2/28 (7.1%)19/28 (67.9%)
DBE: MT-7117 High Dose Switched From Placebo0/28 (0%)1/28 (3.6%)18/28 (64.3%)
DBE: MT-7117 Low Dose0/56 (0%)1/56 (1.8%)24/56 (42.9%)
DBE: MT-7117 High Dose0/54 (0%)2/54 (3.7%)21/54 (38.9%)
Most frequent serious events
Most frequent serious events
EventDBT: PlaceboDBT: MT-7117 Low DoseDBT: MT-7117 High DoseDBE: MT-7117 Low Dose Switched From PlaceboDBE: MT-7117 High Dose Switched From PlaceboDBE: MT-7117 Low DoseDBE: MT-7117 High Dose
Hepatic enzyme increasedInvestigations0/610/630/602/280/280/560/54
Porphyria non-acuteCongenital, familial and genetic disorders0/610/630/600/281/280/560/54
OesophagitisGastrointestinal disorders0/610/630/600/280/280/561/54
Fibula fractureInjury, poisoning and procedural complications0/610/630/600/280/280/561/54
PericarditisCardiac disorders0/610/630/600/280/281/560/54
CholestasisHepatobiliary disorders0/610/631/600/280/280/560/54
AsthmaRespiratory, thoracic and mediastinal disorders0/610/631/600/280/280/560/54
MyocarditisCardiac disorders0/611/630/600/280/280/560/54
Meningitis viralInfections and infestations0/611/630/600/280/280/560/54
Most frequent other events
Showing 10 of 31
Most frequent other events
EventDBT: PlaceboDBT: MT-7117 Low DoseDBT: MT-7117 High DoseDBE: MT-7117 Low Dose Switched From PlaceboDBE: MT-7117 High Dose Switched From PlaceboDBE: MT-7117 Low DoseDBE: MT-7117 High Dose
COVID-19Infections and infestations2/615/631/607/288/2811/5610/54
NauseaGastrointestinal disorders4/614/6317/601/285/281/562/54
HeadacheNervous system disorders3/618/639/602/283/282/562/54
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/616/638/604/283/283/562/54
DiarrhoeaGastrointestinal disorders1/615/638/600/281/280/561/54
Skin hyperpigmentationSkin and subcutaneous tissue disorders1/613/638/602/283/280/560/54
Aspartate aminotransferase increasedInvestigations1/614/630/603/281/281/561/54
Blood creatine phosphokinase increasedInvestigations0/611/631/603/280/281/560/54
Vitamin D deficiencyMetabolism and nutrition disorders0/611/630/603/281/283/562/54
ParaesthesiaNervous system disorders0/611/630/603/281/280/560/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboMT-7117 Low DoseMT-7117 High DoseTotal
<=18 years12131237
Between 18 and 65 years474546138
>=65 years2529
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMT-7117 Low DoseMT-7117 High DoseTotal
Female30303393
Male31332791
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMT-7117 Low DoseMT-7117 High DoseTotal
Hispanic or Latino77216
Not Hispanic or Latino535258163
Unknown or Not Reported1405
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMT-7117 Low DoseMT-7117 High DoseTotal
American Indian or Alaska Native0000
Asian91212
Native Hawaiian or Other Pacific Islander0011
Black or African American0000
White526055167
More than one race0000
Unknown or Not Reported0224
08

Study locations

31 sites
  • Marvel Clinical Research, LLC
    Huntington Beach, California 92647, United States
  • University Of Miami School Of Medicine, Center For Liver Diseases
    Miami, Florida 33136, United States
  • MetroBoston Clinical Partners, LLC
    Brighton, Massachusetts 02135, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
    New York, New York 10029, United States
  • Wake Forest University Baptist Health
    Winston-Salem, North Carolina 27109, United States
  • Remington-Davis Clinical Research
    Columbus, Ohio 43215, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • The University of Texas Medical Branch (UTMB)
    Galveston, Texas 77555, United States
  • University of Washington-Seattle Cancer Care Alliance
    Seattle, Washington 19023, United States
  • The Wesley Hospital
    Brisbane, Queensland 4066, Australia
  • Royal Melbourne Hospital (RMH)
    Melbourne, Victoria 3050, Australia
  • University of Alberta
    Edmonton, Alberta AB T6G 2R3, Canada
  • Westfaelische Wilhelms-Universitaet Muenster
    Münster, Northrhein Westalien 48149, Germany
  • Charite - Universitaetsmedizin Berlin
    Berlin, 10117, Germany
  • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
    Brescia, 1 25123, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano
    Milan, 20122, Italy
  • U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena
    Modena, 41125, Italy
  • I.F.O Hospital Centro Porfirie e Malattie Rare
    Rome, 144 Rome RM, Italy
  • Kobe University Hospital
    Kobe, Hyōgo, Japan
  • Sophia Dermatology Clinic
    Kanazawa, Ishikawa-ken 921-8035, Japan
  • Investigator site
    Sayama, Osaka, Japan
  • Osaka Medical College Hospital
    Takatsuki, Osaka, Japan
  • Tokyo Saiseikai Central Hospital
    Minato-ku, Tokyo, Japan
  • Toyama University Hospital
    Sugitani, Toyama 930-0194, Japan
  • Haukeland University Hospital
    Bergen, Norway
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Karolinska University Hospital
    Stockholm, 171 64, Sweden
  • University of Manchester
    Salford, Manchester M13 9PL, United Kingdom
  • Evelina London Children's Hospital - Guy's & St Thomas' NHS Foundation Trust
    London, SE1 7EH, United Kingdom
09

References and documents

Publications

  • Ogasawara A, Ide R, Inoue S, Tsuda M, Teng R. Assessment of Potential Drug-Drug Interactions for Novel Oral Melanocortin-1 Receptor Agonist Dersimelagon. Pharmacol Res Perspect. 2025 Feb;13(1):e70069. doi: 10.1002/prp2.70069. PubMed 39887900 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Dec 2021, 18 months.

Results were first posted in Mar 2025, 3 years 3 months after primary completion. A results delay was requested in Dec 2022.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2020
First posted
May 26, 2020
StartActual
Jun 1, 2020
Primary completionActual
Dec 14, 2021
CompletionActual
Jul 26, 2022
Results delay requested
Dec 5, 2022
Results first posted
Mar 21, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04402489
Responsible party
Sponsor
First posted
May 26, 2020
Start date
Jun 1, 2020
Primary completion
Dec 14, 2021
Completion
Jul 26, 2022
Results posted
Mar 21, 2025
Last update
Dec 30, 2025

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion